Search results for "therapy [Dwarfism]"

showing 10 items of 2401 documents

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a…

2020

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by ad hoc developed ELISA’s. Using specific cut-offs determined…

0301 basic medicineOncologySettore MED/06 - Oncologia MedicaProgrammed Cell Death 1 ReceptorB7-H1 Antigen0302 clinical medicineRenal cell carcinomaPD-1Immunology and AllergyProspective Studiespredictive biomarkerRC254-282ComputingMilieux_MISCELLANEOUSOriginal ResearchbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensfood and beveragesBTN3A1PrognosisTreatment efficacyKidney Neoplasms3. Good healthNivolumabOncology030220 oncology & carcinogenesisBiomarker (medicine)[SDV.IMM]Life Sciences [q-bio]/Immunologysoluble immune-checkpointsNivolumabResearch ArticlePD-L1medicine.medical_specialtyrenal cell carcinomabutyrophilinImmunology03 medical and health sciencesAntigens CDInternal medicinePD-L1mental disordersmedicineHumansIn patientCarcinoma Renal Cellbutyrophilinsbusiness.industryCancercirculating immune checkpointsPlasma levelsRC581-607medicine.diseasecirculating immune checkpoint030104 developmental biologyBTN2A1immunotherapy responsebiology.proteinImmunologic diseases. Allergybusiness
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cance…

2021

Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international regulatory agencies. The current work aims to assess different efficacy and safety profiles among chemoimmunotherapy plus immuno-oncology (CT+IO) approaches according to different immune checkpoint inhibitor (ICI) subtypes. Material & Methods: We included in our meta-analysis six first-line randomised controlled trials (RCTs) comparing the association of single-agent ICI with CT versus CT al…

0301 basic medicineOncologymedicine.medical_specialtyImmunotherapy for Lung Cancer: Progress Opportunities and Challengesmedicine.medical_treatmentCellFood and drug administration03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemo-immunotherapy ES-SCLC indirect comparison meta-analysis PD-L1/PD-1 inhibitorsChemo immunotherapyRC254-282ChemotherapyLungbusiness.industryPD-L1/PD-1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensIndirect comparison030104 developmental biologymedicine.anatomical_structureOncologyindirect comparison030220 oncology & carcinogenesisMeta-analysischemo-immunotherapybusinessExtensive-stage small cell lung cancerES-SCLCMeta-AnalysisTherapeutic Advances in Medical Oncology
researchProduct

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

2016

Abstract Purpose : Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), but its precise characterization remains elusive. We aimed at investigating the immunosuppressive role of high-density neutrophils in HL. Experimental design : First, N-HL function was evaluated in vitro, showing increased arginase (Arg-1) expression and activity compared to healthy subjects. Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, training (N=40) and validation (N=78) sets. Results : s-Arg-1 was higher in patients with advanced stage (p=0.045), B-symptoms (p=0.0048) and a positive FDG-PET scan after two cycles of chemotherapy (PET-2, p=0.012). Baseline levels of s-Arg-1 &g…

0301 basic medicineOncologymedicine.medical_specialtyPrognostic variableMyeloidmedicine.medical_treatmentImmunologyBiochemistry03 medical and health sciencesInternal medicinemedicineProgression-free survivalChemotherapybusiness.industryImmunosuppressionCell BiologyHematologymedicine.diseaseChemotherapy regimenNeutrophiliaLeukemia030104 developmental biologymedicine.anatomical_structureImmunologymedicine.symptombusinessBlood
researchProduct

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin

2017

// Sergio Rizzo 1, * , Antonina Cangemi 1, * , Antonio Galvano 1, * , Daniele Fanale 1 , Silvio Buscemi 2 , Marcello Ciaccio 3 , Antonio Russo 1 , Sergio Castorina 4, 5, # and Viviana Bazan 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal and Specialistic Medicine (DIBIMIS), Laboratory of Clinical Nutrition, University of Palermo, Palermo, Italy 3 Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, U.O.C. Laboratory Medicine, Policlinico University Hospital, Palermo, Italy 4 Fondazione Mediterranea…

0301 basic medicineOncologymedicine.medical_specialtychemotherapy responseClinical nutritiondoxorubicin03 medical and health sciences0302 clinical medicineInternal medicinemicroRNAmedicineDoxorubicinTriple-negative breast cancershort term starvationtriple negative breast cancer cellsbusiness.industryCancerMicroRNAmedicine.diseaseMolecular medicinemicroRNAstriple negative breast cancer cell030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisImmunologyBreast cancer cellsbusinessChemotherapy response; Doxorubicin; MicroRNAs; Short term starvation; triple negative breast cancer cells; Oncologymedicine.drugResearch PaperOncotarget
researchProduct

The Interplay between Genes and Psychosocial Home Environment on Physical Activity

2018

Introduction Genetic factors contribute to individual differences in physical activity, but it remains uncertain whether the magnitude of the genetic effects is modified by variations in home environments. We aimed to examine to what extent the psychosocial home environment in childhood and adolescence modifies the genetic influences on leisure time physical activity in young adulthood. Methods Participants were Finnish twins (N = 3305) who reported their leisure time physical activity at age 24 yr. The psychosocial home environment was assessed by twins at ages 12, 14, and 17 yr, as well as by their parents when the twins were age 12 yr. Gene–environment interaction modeling was performed …

0301 basic medicineParentsDevelopmental psychology0302 clinical medicineSurveys and QuestionnairesOrthopedics and Sports Medicine030212 general & internal medicineLongitudinal StudiesGene–environment interactionta315Childta515Finlandexerciseta3142twinsFamily Relationsgeneettiset tekijätPsychologyPsychosocialfyysinen aktiivisuusinorganic chemicalsAdolescentlongitudinalPhysical activityMEDLINEPhysical Therapy Sports Therapy and Rehabilitationpsykososiaaliset tekijätpitkittäistutkimushome atmospherecomplex mixturesArticle03 medical and health sciencesFamily relationsLeisure ActivitiesHumansExercisechildhoodnuoret aikuisetkaksostutkimusHome environmentExtramuralfungilapsuusequipment and suppliesTwin studykotiympäristökaksoset030104 developmental biologybacteriaGene-Environment Interactionadolescence
researchProduct

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung can…

2020

The introduction of licensed front-line immunotherapies has heralded a new era for the treatment of non-oncogene-addicted, advanced non-small cell lung cancer (NSCLC). Yet as with all evolutions in clinical management, changes in practice can outpace the availability of the clinical evidence needed to inform subsequent therapeutic decision making. At the time of writing, there is limited available evidence on the optimum therapeutic options after progression on immunotherapy. Further research is needed to define mechanisms of immunotherapy resistance in patients with advanced NSCLC, and to understand the implications for subsequent treatment response. Pending the availability of robust clin…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentNintedanibContext (language use)Angiogenesis InhibitorsAnti-angiogenic drugNon-oncogene-addicted non-small cell lung cancer (NSCLC)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineTumor MicroenvironmentHumansTumor microenvironment (TME)Lung cancerImmune Checkpoint InhibitorsTumor microenvironmentAnti-angiogenic drug; Immunotherapy resistance; Nintedanib; Non-oncogene-addicted non-small cell lung cancer (NSCLC); Tumor microenvironment (TME); Vascular endothelial growth factor (VEGF)Oncogenebusiness.industryVascular endothelial growth factor (VEGF)ImmunosuppressionImmunotherapymedicine.diseaseImmunotherapy resistance030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisNintedanibNon small cellImmunotherapybusiness
researchProduct

Training session intensity affects plasma redox status in amateur rhythmic gymnasts

2016

Purpose: The aim of this study was to examine systemic responses of oxidant/antioxidant status following 2 training sessions of different intensity in amateur rhythmic gymnasts. Methods: Before the experimental training, 10 female gymnasts performed a gradually increased exercise test to assess maximal heart rate, maximal oxygen consumption, and anaerobic threshold. They executed 2 intermittent training sessions separated by 48 h of recovery (48 h-post R): the first was performed at low-moderate intensity (LMI) and the second at high intensity (HI). Blood samples were collected immediately pre- and post-training and 48 h-post R. Hydroperoxide level (OxL) and total antioxidant capacity (TAC)…

0301 basic medicineTraining intensitymedicine.medical_specialtyeducationPhysical Therapy Sports Therapy and RehabilitationFree radicalsmedicine.disease_cause03 medical and health scienceslcsh:GV557-1198.9950302 clinical medicineRhythmInternal medicineHeart rateRegular PapermedicineOrthopedics and Sports MedicineExercise physiologylcsh:Sports medicineAntioxidant capacity; Exercise physiology; Free radicals; Oxidative stress; Reactive oxygen species; Rhythmic gymnastics; Training intensitylcsh:SportsSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' Sportivebusiness.industryRhythmic gymnasticsVO2 max030229 sport sciencesExercise physiologyIntensity (physics)Antioxidant capacityAntioxidant capacity030104 developmental biologyEndocrinologyOxidative stressPhysical therapyAntioxidant capacity Exercise physiology Oxidative stress Free radicals Reactive oxygen species Training intensity Rhythmic gymnasticsbusinesslcsh:RC1200-1245Reactive oxygen speciesSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieAnaerobic exerciseOxidative stressJournal of Sport and Health Science
researchProduct

FROM EPIGENETICS TO ANTI-DOPING APPLICATION: A NEW TOOL OF DETECTION

2017

Eukaryotic genomes transcribe up to 90% of the genomic DNA but only 1–2% of these transcripts encode for proteins, whereas the vast majority are transcribed as non-coding RNAs (ncRNAs). They are divided into short ncRNA, particularly microRNA (miRNA) and small interference RNA (siRNA), and long ncRNAs. Noteworthy, they are unexpectedly stable since they are protected from degradation through different mechanisms: package in exosomes/microvesicles structures, in apoptotic bodies, in HDL lipoprotein, or by RNA binding proteins. For several years already, biomarkers have been used to detect biological disease; in the last years, a requirement appeared to find some of them to unearth the signs …

0301 basic medicinelcsh:SportspbiomarkersHDLChemistryDopingPublic Health Environmental and Occupational HealthBiophysicsPhysical Therapy Sports Therapy and RehabilitationNanotechnologydopingncRNA03 medical and health scienceslcsh:GV557-1198.995030104 developmental biologySettore BIO/10 - BiochimicaexosomeEpigeneticsmiRNA ABP Next generation sequencingncRNAHDL
researchProduct

Early detection of gastric cancer beyond endoscopy - new methods

2021

Early detection of gastric cancer is remaining a challenge. This review summarizes current knowledge on non-invasive methods that could be used for the purpose. The role of traditional cancer markers such as CEA, CA 72-4, CA 19-9, CA 15-3, and CA 12-5 lies mainly in therapy monitoring than early detection. Most extensive studied biomarkers (pepsinogens, ABC method) are aiming at the detection of precancerous lesions with modest sensitivity for cancer. Tests based on the detection of cancer-specific methylation patterns (PanSeer), circulating proteins and mutations in circulating tumour DNA (CancerSEEK), as well as miRNA panels have demonstrated promising results bringing those closer to pra…

0301 basic medicinemedicine.diagnostic_testbusiness.industryGastroenterologyEarly detectionCancerEndoscopymedicine.diseaseSurvival AnalysisExtracellular vesiclesEndoscopy03 medical and health sciences030104 developmental biology0302 clinical medicineStomach Neoplasms030220 oncology & carcinogenesismicroRNACancer researchHumansMedicineTherapy monitoringbusinessEarly Detection of CancerBest Practice & Research Clinical Gastroenterology
researchProduct